SEMPREX D is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Endo Pharmaceuticals Inc.. The primary component is Acrivastine; Pseudoephedrine Hydrochloride.
| Product ID | 52244-404_21d2a8a6-108c-4c1d-b1ee-c14f6f2dadc6 |
| NDC | 52244-404 |
| Product Type | Human Prescription Drug |
| Proprietary Name | SEMPREX D |
| Generic Name | Acrivastine And Pseudoephedrine Hydrochloride |
| Dosage Form | Capsule |
| Route of Administration | ORAL |
| Marketing Start Date | 2012-01-26 |
| Marketing End Date | 2020-12-31 |
| Marketing Category | NDA / NDA |
| Application Number | NDA019806 |
| Labeler Name | Endo Pharmaceuticals Inc. |
| Substance Name | ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE |
| Active Ingredient Strength | 8 mg/1; mg/1 |
| Pharm Classes | Histamine H1 Receptor Antagonists [MoA],Histamine-1 Receptor Antagonist [EPC],Adrenergic alpha-Agonists [MoA],alpha-Adrenergic Agonist [EPC] |
| NDC Exclude Flag | N |
| Marketing Start Date | 2012-01-26 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA019806 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2012-01-26 |
| Ingredient | Strength |
|---|---|
| ACRIVASTINE | 8 mg/1 |
| SPL SET ID: | d86c6a13-9e5f-43c2-92f5-c7ed7bfcedfc |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() SEMPREX 78429596 3023249 Live/Registered |
ACTIENT PHARMACEUTICALS LLC 2004-06-03 |
![]() SEMPREX 74338456 1879087 Dead/Cancelled |
Burroughs Wellcome Co. 1992-12-09 |
![]() SEMPREX 73514851 1421747 Live/Registered |
SEMPREX CORPORATION 1984-12-24 |